388 related articles for article (PubMed ID: 30498492)
1. Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.
Lancman G; Arinsburg S; Jhang J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richter J; Chari A
Front Immunol; 2018; 9():2616. PubMed ID: 30498492
[TBL] [Abstract][Full Text] [Related]
2. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
[TBL] [Abstract][Full Text] [Related]
3. Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions.
Song J; Fu R
J Clin Lab Anal; 2021 Dec; 35(12):e23832. PubMed ID: 34752645
[TBL] [Abstract][Full Text] [Related]
4. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing.
De Vooght KM; Oostendorp M; van Solinge WW
Curr Opin Hematol; 2016 Nov; 23(6):557-562. PubMed ID: 27389485
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab: Therapeutic asset, biological trap!
Deneys V; Thiry C; Frelik A; Debry C; Martin B; Doyen C
Transfus Clin Biol; 2018 Feb; 25(1):2-7. PubMed ID: 29336950
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
[TBL] [Abstract][Full Text] [Related]
7. Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform?
Habicht CP; Ridders M; Grueger D; Adolph S; Immenschuh S; Schneeweiss C
Transfusion; 2023 Apr; 63(4):808-816. PubMed ID: 36707937
[TBL] [Abstract][Full Text] [Related]
8. Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy.
Anani WQ; Marchan MG; Bensing KM; Schanen M; Piefer C; Gottschall JL; Denomme GA
Transfusion; 2017 Jun; 57(6):1470-1479. PubMed ID: 28150308
[TBL] [Abstract][Full Text] [Related]
9. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.
Oostendorp M; Lammerts van Bueren JJ; Doshi P; Khan I; Ahmadi T; Parren PW; van Solinge WW; De Vooght KM
Transfusion; 2015 Jun; 55(6 Pt 2):1555-62. PubMed ID: 25988285
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
Chami B; Okuda M; Moayeri M; Pirenne F; Hidaka Y; Nambiar A; Song Z; Bedel O; Zhang B; Hopke J; Deng G; Zhu C; Macé S; Chiron M; Adrian F; Fukao T; Basile FG; Martin T
Transfusion; 2022 Nov; 62(11):2334-2348. PubMed ID: 36239134
[TBL] [Abstract][Full Text] [Related]
11. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.
Chari A; Arinsburg S; Jagannath S; Satta T; Treadwell I; Catamero D; Morgan G; Feng H; Uhlar C; Khan I; Doshi P; Usmani S
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):44-51. PubMed ID: 29054515
[TBL] [Abstract][Full Text] [Related]
12. How do I work up pretransfusion samples containing anti-CD38?
Anani WQ; Duffer K; Kaufman RM; Denomme GA
Transfusion; 2017 Jun; 57(6):1337-1342. PubMed ID: 28474469
[TBL] [Abstract][Full Text] [Related]
13. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
[TBL] [Abstract][Full Text] [Related]
14. Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies.
Carreño-Tarragona G; Cedena T; Montejano L; Alonso R; Miras F; Valeri A; Rivero A; Lahuerta JJ; Martinez-Lopez J
Transfus Med; 2019 Jun; 29(3):193-196. PubMed ID: 29369430
[TBL] [Abstract][Full Text] [Related]
15. Impact of new myeloma agents on the transfusion laboratory.
Jones AD; Moayeri M; Nambiar A
Pathology; 2021 Apr; 53(3):427-437. PubMed ID: 33707006
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
17. Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
Zannetti BA; Faini AC; Massari E; Geuna M; Maffini E; Poletti G; Cerchione C; Martinelli G; Malavasi F; Lanza F
Cells; 2020 Dec; 9(12):. PubMed ID: 33322499
[TBL] [Abstract][Full Text] [Related]
18. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.
Phou S; Costello C; Kopko PM; Allen ES
Transfusion; 2021 Jul; 61(7):2054-2063. PubMed ID: 33960433
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
20. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
